Obesity Clinical Trial
Official title:
Effectiveness and Cost-Effectiveness of Fully-Automated Digital vs. Human Coach-Based Diabetes Prevention Programs
Verified date | December 2023 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this research study is to compare the effectiveness of a fully automated digital diabetes prevention program to standard of care human coach-based diabetes prevention programs for promoting clinically meaningful lifestyle changes to reduce the risk of type 2 diabetes in adults with prediabetes.
Status | Active, not recruiting |
Enrollment | 368 |
Est. completion date | June 30, 2025 |
Est. primary completion date | January 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Provision of signed and dated informed consent form. - Stated willingness to comply with all study procedures and availability for the duration of the study. - Laboratory evidence of prediabetes, defined as any of the following lab results, in the past year: 1. Hemoglobin A1C 5.7% to 6.4% 2. Fasting glucose 100-125 mg/dL 3. Plasma glucose of 140-199 mg/dL measured 2 hours after a 75 gm glucose load - Body mass index (BMI) =25 kg/m2 (or=23 kg/m2 for Asians). - Proficiency in reading English. - Smartphone user (Android Operating System (OS) 9.0 or iOS 13.3 or newer). - Plans to reside in recruitment area for the next 12 months (participant's zip code of residence is within ~45 miles of the study recruitment site. Exclusion Criteria: - Medical conditions that prevent adoption of moderate physical activity (per primary care clinician). - Aortic stenosis. - Unstable cardiac disease (myocardial infarction, heart failure, or stroke in previous 6 months, currently participating in cardiac rehabilitation). - Has a pacemaker, implantable cardioverter-defibrillator (ICD), or other implanted electronic device. - Use of any glucose-lowering medications, weight loss medications, or any systemic glucocorticoids within the previous 3 months. - Active malignancy of any type or diagnosed with or treated for cancer within the past 2 years. Individuals with basal and squamous cell carcinoma of the skin that has been successfully treated will be allowed to participate. - Diagnosis of diabetes mellitus. - Pregnancy or planned pregnancy in the next 12 months. - Anemia. - Receiving treatment for iron-deficiency anemia, vitamin B12 deficiency, or folate d efficiency. - Hemoglobinopathy (HbS or HbC disease). - Blood transfusion in previous 4 months. - On dialysis or active organ transplant list. - Treated with erythropoietin. - Major psychiatric disorder (schizophrenia) or use of antipsychotic medications within the past 1 year. - Dementia or Alzheimer's disease. - Diagnosed with an eating disorder (anorexia nervosa, avoidant/restrictive food intake disorder, binge eating disorder, bulimia nervosa, Pica, rumination disorder, other specified or unspecified feeding or eating disorder) - Diagnosed or self-reported alcohol or substance abuse. - Known allergy to steel. - Participation in another clinical trial related to lifestyle management or diabetes prevention. - Currently attending or attended a diabetes prevention program in the previous 2 years. - Unwilling to accept random assignments. - Had bariatric surgery within the 12 months prior randomization or is planning to undergo bariatric surgery during the study. |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins Hospital | Baltimore | Maryland |
United States | Reading Hospital - Tower Health | Reading | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Achievement of CDC's benchmark for type 2 diabetes risk reduction as a binary outcome (yes/no) | The achievement is defined as attainment of one or more of the following:
At least 5% weight loss at 12 months. At least 4% weight loss at 12 months and at least 150 minutes/week of physical activity (measured using monthly serial Actigraphy and averaged over months 1-11) At least 0.2% reduction in A1C at 12 months (for participants whose A1C result obtained at baseline study visit is between 5.7% and 6.4%). |
12 months | |
Secondary | Cost-effectiveness as assessed by the Markov model | The investigators will compare the cost-effectiveness of the two interventions based on lifetime horizon by constructing a Markov model with model parameters populated from the trial results as well as other published literature. The model will estimate the incremental cost-effectiveness ratio between the two interventions. | 12 months | |
Secondary | Change in hemoglobin A1C | Change in HbA1C (percentage) from baseline to 6 months and 12 months | Baseline, 6 months and 12 months | |
Secondary | Percentage weight change | Percentage weight (percent) change from baseline to 6 and 12 months | Baseline, 6 months and 12 months | |
Secondary | Absolute weight change | Absolute weight change (kilograms) from baseline to 6 and 12 months | Baseline, 6 months and 12 months | |
Secondary | Change in physical activity - average minutes/week of physical activity | Change in physical activity measure (average minutes/week of physical activity) assessed using blinded Actigraphy (monthly serial consecutive 7-days wear period) from baseline to 6 months and 12 months. | Baseline, 6 months and 12 months | |
Secondary | Change in physical activity - hours per week of physical activity | Change in physical activity measure (metabolic equivalent task (MET)-hours per week of physical activity) assessed using blinded Actigraphy (monthly serial consecutive 7-days wear period) from baseline to 6 months and 12 months. | Baseline, 6 months and 12 months | |
Secondary | Change in physical activity - average number of steps per day | Change in physical activity measures (average number of steps per day) assessed using blinded Actigraphy (monthly serial consecutive 7-days wear period) from baseline to 6 months and 12 months. | Baseline, 6 months and 12 months | |
Secondary | Engagement with programs as assessed by a score out of 100% | To compare engagement with digital vs. human coach-based DPPs and evaluate whether between-group differences in clinical outcomes are mediated by engagement, the investigators will define an engagement score (out of 100%) for the hDPP based on the percentage of total number of sessions attended, using the most current CDC engagement definitions at the time of completion of the study. Percentage engagement will be defined out of a total of 8 sessions in month 1-6. An engagement score (out of 100%) for the dDPPs will based on percentage of full weeks during which the app is installed and a) both push notifications and motion sensors are enabled or b) the participant accesses any component within the app for months 1-6. | 6 months | |
Secondary | Engagement with programs as assessed by a score out of 100% | To compare engagement with digital vs. human coach-based DPPs and evaluate whether between-group differences in clinical outcomes are mediated by engagement, the investigators will define an engagement score (out of 100%) for the hDPP based on the percentage of total number of sessions attended, using the most current CDC engagement definitions at the time of completion of the study. Percentage engagement will be defined out of a total of 3 sessions in month 7-12. An engagement score (out of 100%) for the dDPPs will based on percentage of full weeks during which the app is installed and a) both push notifications and motion sensors are enabled or b) the participant accesses any component within the app for months 7-12 | 12 months | |
Secondary | Incidence of type 2 diabetes | Percentage of individuals who develop type 2 diabetes (A1C =6.5%). | 6 months | |
Secondary | Incidence of type 2 diabetes | Percentage of individuals who develop type 2 diabetes (A1C =6.5%). | 12 months | |
Secondary | Acceptability as assessed by the 32-item acceptability questionnaire | To compare the acceptability of the two interventions (satisfaction, utility, interest, motivation, user experience, etc.) using the 32-item acceptability questionnaire.
Scoring: Sum up all responses to questions 1-31, divide by 155, and multiply by 100 to calculate percentage score out of 100%. The range of possible scores is 20% (lowest acceptability) to 100% (highest possible acceptability). |
6 months | |
Secondary | Acceptability as assessed by the 32-item acceptability questionnaire | To compare the acceptability of the two interventions (satisfaction, utility, interest, motivation, user experience, etc.) using the 32-item acceptability questionnaire.
Scoring: Sum up all responses to questions 1-31, divide by 155 and multiply by 100 to calculate percentage score out of 100%. The range of possible scores is 20% (lowest acceptability) to 100% (highest possible acceptability). |
12 months | |
Secondary | Correlation between self-reported and measured physical activity | To evaluate the correlation between self-reported PA data collected using different methods:
Data collected and reported by hDPPs Self-reported PA data collected by study team obtained at 1-month intervals Objectively measured PA data (Actigraphy) obtained at 1-month intervals |
6 months and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |